BridgeBio Oncology Therapeutics, Inc. (NasdaqGM: BBOT)
Health Care · Biotechnology · US
$3.27
-1.21% today · -71.1% 1Y
BridgeBio Oncology Therapeutics, Inc. (NasdaqGM: BBOT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $265.38M and employs 88 people.
Over the last twelve months the share price has lost 71.1%, trading between 3.27 and 14.87.
Tweenvest scores BridgeBio Oncology Therapeutics, Inc. across four factors: quality 56/100, value 23/100. Its strongest factor is quality.
BBOT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $265.38M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.56
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- $14.87
- 52-week low
- $3.27
- Avg volume (3M)
- —
- Shares outstanding
- 80.17M
- Employees
- 88
- Next earnings
- —
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- ISIN
- US1079241022
- Founded
- 2016
- Listed since
- Aug 12, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Palisade Bio, Inc.NasdaqCM: PALI | $268.38M | $1.58 | +2.60% |
| Northwest Biotherapeutics, Inc.OTCPK: NWBO | $267.79M | $0.16 | +2.15% |
| Century Therapeutics, Inc.NasdaqCM: IPSC | $266.18M | $1.45 | -1.36% |
| Mabpharm LimitedSEHK: 2181 | $265.39M | HK$0.51 | +3.06% |
| Lexeo Therapeutics, Inc.NasdaqGM: LXEO | $265.00M | $3.14 | -2.94% |
| Inventage Lab, Inc.KOSDAQ: A389470 | $263.31M | ₩26,600.00 | -6.01% |
| Santhera Pharmaceuticals Holding AGSWX: SANN | $263.01M | CHF14.58 | +2.10% |
| Obigen Pharma Inc.TPEX: 7876 | $262.25M | NT$78.20 | +21.81% |
Figures last refreshed Oct 11, 2026.